title: A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.
abstract: The meta-analytic approach to evaluating surrogate end points assesses the predictiveness of treatment effect on the surrogate toward treatment effect on the clinical end point based on multiple clinical trials. Definition and estimation of the correlation of treatment effects were developed in linear mixed models and later extended to binary or failure time outcomes on a case-by-case basis. In a general regression setting that covers nonnormal outcomes, we discuss in this paper several metrics that are useful in the meta-analytic evaluation of surrogacy. We propose a unified 3-step procedure to assess these metrics in settings with binary end points, time-to-event outcomes, or repeated measures. First, the joint distribution of estimated treatment effects is ascertained by an estimating equation approach; second, the restricted maximum likelihood method is used to estimate the means and the variance components of the random treatment effects; finally, confidence intervals are constructed by a parametric bootstrap procedure. The proposed method is evaluated by simulations and applications to 2 clinical trials.
authors.affiliation: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. jdai@fhcrc.org
authors.forename: James Y
authors.initials: JY
authors.lastname: Dai
authors.forename: James P
authors.initials: JP
authors.lastname: Hughes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001521:Behavior Therapy; D015415:Biomarkers / Q000032:analysis*; D003198:Computer Simulation; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D005260:Female; D006678:HIV / Q000254:growth & development; D015658:HIV Infections / Q000517:prevention & control / Q000523:psychology; D018451:Homosexuality, Male / Q000523:psychology; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D015233:Models, Statistical; D010051:Ovarian Neoplasms / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers